Maxigesic 325 + Acetaminophen + Ibuprofen + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Dental Pain

Conditions

Dental Pain

Trial Timeline

Apr 1, 2013 → Jan 1, 2015

NCT ID

NCT01420653

About Maxigesic 325 + Acetaminophen + Ibuprofen + Placebo

Maxigesic 325 + Acetaminophen + Ibuprofen + Placebo is a phase 3 stage product being developed by AFT Pharmaceuticals for Dental Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01420653. Target conditions include Dental Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01420653	Phase 3	Completed	Apr 1, 2013	Jan 1, 2015	Dental Pain

Competing Products

20 competing products in Dental Pain

See all competitors

Product	Company	Stage	Hype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tablet	Johnson & Johnson	Phase 3	77
Sodium Fluoride Dentifrice	Johnson & Johnson	Pre-clinical	23
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + Placebo	Johnson & Johnson	Phase 3	77
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + Placebo	Johnson & Johnson	Phase 2	52
2 mg nicotine gum + 4 mg nicotine gum	Johnson & Johnson	Approved	85
Acetaminophen ER + Placebo	Johnson & Johnson	Phase 2	52
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsule	Johnson & Johnson	Phase 3	77
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassium	Novartis	Phase 3	77
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	51
Pregabalin + Alprazolam + Placebo	Pfizer	Phase 2	51
Prototype (AN0128 Toothpaste)	Pfizer	Phase 1	32
PF-05089771 + PF-05089771 + PF-05089771 + Ibuprofen	Pfizer	Phase 2	51
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	51
PF-04531083 + PF-04531083 + Ibuprofen	Pfizer	Phase 2	51
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + Placebo	Bayer	Phase 3	74
XPF-001 + placebo	Xenon Pharmaceuticals	Phase 2	49
N1539 + placebo + N1539 + N1539 + Motrin	Alkermes	Phase 2	49
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placebo	Organon	Phase 3	72
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + Placebo	AFT Pharmaceuticals	Phase 2	44
C16G2 Gel	Armata Pharmaceuticals	Phase 2	44

Other Products from AFT Pharmaceuticals

Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)Phase 3

Maxigesic IV + IV Acetaminophen + IV Ibuprofen + Placebo IVPhase 3

Maxigesic® IVPhase 3

Acetaminophen + Maxigesic 325 + Ibuprofen + PlaceboPhase 3

Combogesic® tablets + Acetaminophen 500mg + PlaceboPhase 3